FIGURE 5 from Discovery and Preclinical Activity of BMS-986351, an Antibody to SIRPα That Enhances Macrophage-mediated Tumor Phagocytosis When Combined with Opsonizing Antibodies

Cross-reactivity of BMS-986351 in human (A), cynomolgus monkey (B), rat (C), and mouse (D). E, Immunophenotyping by multiparameter flow cytometry in human and cynomolgus monkeys shows that most CD14-positive cells (monocytes) also bind BMS-986351. F, Proportion of live cells expressing CD14 that bind BMS-986351 in humans and cynomolgus monkeys. G, Binding of BMS-986351 in specific lymphoid and myeloid cell subsets. Pharmacokinetic profiles (day 1 to 15; H) and hematology assessment (days 4, 7, and 28; I) of BMS-986351 dosed in cynomolgus monkeys (n = 3) at 10, 30, and 100 mg/kg. MFI, mean fluorescence intensity.